Alemtuzumab THERAPY

INDICATIONS FOR USE:

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>ICD10</th>
<th>Protocol Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features</td>
<td>G35</td>
<td>MS100</td>
</tr>
</tbody>
</table>

ELIGIBILITY:

- Indications as above
- Patient aged 18-55 (use with caution outside of this age range)
- Women of childbearing potential should use effective contraceptive measures during treatment and for 4 months following a course of alemtuzumab treatment

EXCLUSIONS:

- Hypersensitivity to alemtuzumab or to any of the known excipients
- HIV infection

USE with CAUTION:

- In patients with previous autoimmune conditions e.g. ITP, thyroid disorders, nephropathies
- In pregnancy and lactation

TESTS:

Baseline Measures:
MRI 3 months prior to treatment

Baseline tests:
- FBC, U&E, LFTs and TFT
- Urinalysis and microscopy
- HIV test
- Varicella Zoster Virus (VZV) Serology
NDMP Multiple Sclerosis Treatment Protocol

- All vaccinations must be completed 6 weeks prior to treatment
- Ensure cervical (HPV) screening has been carried out for female patients,
- Evaluation for active or latent TB as per local guidelines
- Screening patients at high risk of HBV and/or HCV infection before initiation of alemtuzumab should be considered. Caution should be exercised in prescribing alemtuzumab to patients identified as carriers of HBV and/or HCV as these patients may be at risk of irreversible liver damage relative to a potential virus reactivation as a consequence of their pre-existing status.
- Annual cervical (HPV) screening for female patients

Regular tests:
FBC, serum creatinine levels, urinalysis with microscopy at monthly intervals.
Thyroid Function Tests every 3 months.
A MRI scan should be performed within 3 months of each course of treatment to allow for assessment of disease response.

These laboratory tests should be conducted at periodic intervals for 48 months following the last treatment course of alemtuzumab in order to monitor for early signs of autoimmune disease:

Disease monitoring:
Disease monitoring should be in line with the patient’s treatment plan and any other test/s as directed by the supervising Consultant. An annual MRI scan for disease activity should be carried out. An EDSS score should be included prior to each treatment or change to treatment.

TREATMENT:
Alemtuzumab therapy is recommended as 2 treatment courses, (Day 1-5 on Year 1 and Day 1-3 on Year 2) with safety follow-up of patients from initiation of treatment and until 48 months after the last infusion.

In the extension phases of the phase 3 clinical trials a 3rd cycle was given in patients if there was a single clinical relapse or two new MRI lesions. A third dose should not be used where the clinician considers the patient not to have fully responded to the
The information contained in this document is a statement of consensus from the National Clinical Programme for Neurology regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these documents is the responsibility of the prescribing clinician. and is subject to HSE’s terms of use available at http://www.hse.ie/eng/Disclaimer

This information is valid only on the day of printing, for any updates please check http://www.hse.ie/eng/about/Who/acuta/

NDMP Multiple Sclerosis Treatment Protocol

2nd treatment course i.e. in cases where there is breakthrough clinical or MRI activity at least 12 months since the last course.

<table>
<thead>
<tr>
<th>Day</th>
<th>Drug</th>
<th>Dose</th>
<th>Route</th>
<th>Diluent &amp; Rate</th>
<th>Cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-5</td>
<td>Alemtuzumab</td>
<td>12mg</td>
<td>IV infusion</td>
<td>100ml 0.9% NaCl or 5% glucose over 4 hours</td>
<td>1</td>
</tr>
<tr>
<td>12 months later</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-3</td>
<td>Alemtuzumab</td>
<td>12mg</td>
<td>IV infusion</td>
<td>100ml 0.9% NaCl or 5% glucose over 4 hours</td>
<td>2</td>
</tr>
</tbody>
</table>

Missed doses should not be given on the same day as a scheduled dose.

Resources for the management of anaphylaxis or serious reactions should be available.

**DOSE MODIFICATIONS:**
- No recommended dose modifications

**Renal and Hepatic impairment:**
Alemtuzumab has not been studied in patients with renal or hepatic impairment

**SUPPORTIVE CARE:**

**PREMEDICATIONS:**
Patients should be pre-treated with corticosteroids (such as 1,000mg methylprednisolone) immediately prior to alemtuzumab administration on each of the first 3 days of any treatment course.
Additionally, pre-treatment with antihistamines and/or antipyretics prior to alemtuzumab administration may also be considered.

**TAKE HOME MEDICATIONS:**
Oral prophylaxis for herpes infection (such as acyclovir 200mg twice a day or equivalent) should be administered to all patients starting on the first day of each treatment course and continuing for a minimum of 1 month following treatment with alemtuzumab.
Listeriosis/Listeria meningitis has been reported in patients treated with alemtuzumab, generally within one month of infusion. To reduce this risk, patients receiving alemtuzumab should avoid ingestion of uncooked or undercooked meats, soft cheeses and unpasteurized dairy products for at least one month after treatment.

**ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS**

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details. **This medicinal product is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions.**

**Autoimmunity:** Treatment may result in the formation of autoantibodies and increase the risk of autoimmune mediated conditions including immune thrombocytopenic purpura (ITP), thyroid disorders or, rarely, nephropathies (e.g. anti-glomerular basement membrane disease). Caution should be exercised in patients with previous autoimmune conditions other than MS, although available data suggests there is no worsening of pre-existing autoimmune conditions after alemtuzumab treatment.

**Infusion-Associated Reactions** (IARs): It is recommended that patients be premedicated to ameliorate the effects of infusion reactions as detailed above. IARs may occur in patients despite pretreatment. Observation for infusion reactions is recommended during and for 2 hours after alemtuzumab infusion. If an IAR occurs, provide the appropriate symptomatic treatment, as needed. If the infusion is not well tolerated, the infusion duration may be extended. If severe infusion reactions occur, immediate discontinuation of the intravenous infusion should be considered. Physicians should be aware of the patient’s cardiac history as infusion-associated reactions can include cardiac symptoms such as tachycardia.

**Infections:** Infections may occur at a higher rate in patients treated with alemtuzumab. For more detail please refer to the SmPC.
**Concurrent treatment with immunosuppressants:** Alemtuzumab has not been administered for treatment of MS concomitantly with or following antineoplastic or immunosuppressive therapies. As with other immunomodulating therapies, potential combined effects on the patient’s immune system should be taken into account when considering administration of alemtuzumab. Concomitant use of alemtuzumab with any of these therapies could increase the risk of immunosuppression.

**DRUG INTERACTIONS:**
- No formal drug interaction studies have been conducted with alemtuzumab using the recommended dose in patients with MS.
- Current drug interaction databases should be consulted for more information.

**SUPPORT RESOURCES:**
*Please note that this is for information only and does not constitute endorsement by the NDMP*


**ATC CODE:**
Alemtuzumab L04AA34

**REIMBURSEMENT CATEGORY:**
National Drugs Management Scheme (NDMS)

**PRESCRIPTIVE AUTHORITY:**
The treatment plan must be initiated by a Consultant Neurologist experienced in the treatment of MS.

<table>
<thead>
<tr>
<th>Protocol: MS - Alemtuzumab</th>
<th>Published: 23/02/2017</th>
<th>Version number: 1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Review: 22/02/2020</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NDMP Protocol Code: MS100</th>
<th>Contributor: Prof. Tim Lynch as Clinical Lead of the National Clinical Programme for Neurology</th>
<th>Page 5 of 6</th>
</tr>
</thead>
</table>

The information contained in this document is a statement of consensus from the National Clinical Programme for Neurology regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE’s terms of use available at [http://www.hse.ie/eng/disclaimer](http://www.hse.ie/eng/disclaimer). This information is valid only on the day of printing; for any updates please check [http://www.hse.ie/eng/about/Who/acute](http://www.hse.ie/eng/about/Who/acute).
REFERENCES:

Comments and feedback welcome at ndmp@hse.ie.